The overarching goal of this study is to understand how BEST1 expression is modulated by cis-regulatory elements in the retinal pigment epithelium (RPE). The variability of retinal phenotypes and age of onset of visual loss, even in individuals who carry the same causative mutation, is one of the biggest mysteries for BEST1 related diseases. Genetic variations in non-coding regulatory elements can serve as an attractive model to provide the molecular basis for the observed various onsets of BEST1 vitelliform macular dystrophy (BVMD) in patients. Therefore understanding the transcriptional control mediated by cis-regulatory elements in the RPE will give us insight into novel target regions for therapeutic editing of the enhancer elements identified by this study. We are utilizing human induced pluripotent stem cells (iPSCs)-derived RPEs as a model to understand cell type-specific transcriptional controls of BEST1. We are also utilizing integrative, unbiased, and high throughput epigenomic and genetic tools to achieve the following aims: (1) We will use a high resolution 4C-seq analysis to identify potential regulatory elements that interact with the BEST1 promoter in human primary RPE. (2) In Aim 2, we will generate BEST1 dual allele reporter lines and use these lines to interrogate cis-regulatory elements of BEST1 in their native chromatin contexts utilizing high throughput CRIPSR/Cas9 mediated genome editing approach. (3) Finally, we will test the utilities of allelic specific enhancer deletion to modulate allelic expression of BEST1. We expect these analyses will significantly advance our knowledge of the precise control of BEST1 transcription in RPEs.

Public Health Relevance

Elucidating the molecular mechanism of BEST1 gene regulation will greatly advance our understanding of various onset of incurable BEST1-related blindness. The outcome of this study will provide the molecular basis for new drug targets and places for therapeutic editing via modulating allelic expression of BEST1. The proposed system will have a wide implication to other dominant negative eye disease with various clinical phenotypes and various ages of onset.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY027789-02
Application #
9564118
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Neuhold, Lisa
Project Start
2017-09-30
Project End
2022-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Li, Yun; Hu, Ming; Shen, Yin (2018) Gene regulation in the 3D genome. Hum Mol Genet 27:R228-R233